Download PDF
Thromb Haemost 1999; 81(05): 673-675
DOI: 10.1055/s-0037-1614551
Rapid Communication
Schattauer GmbH

Hormone Replacement Therapy and Circulating ICAM-1 in Postmenopausal Women

A Randomised Controlled Trial
Pierre-Yves Scarabin
2   Laboratory of Haemostasis and INSERM Unit 428, Hôpital Broussais, Paris, France
,
Martine Alhenc-Gelas
1   From the INSERM, Cardiovascular Epidemiology Unit U258, Hôpital Broussais
,
Emmanuel Oger
2   Laboratory of Haemostasis and INSERM Unit 428, Hôpital Broussais, Paris, France
,
Geneviève Plu-Bureau
2   Laboratory of Haemostasis and INSERM Unit 428, Hôpital Broussais, Paris, France
› Author Affiliations
Further Information

Publication History

Received 03 December 1998

Accepted after revision 10 February 1999

Publication Date:
09 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Hormone replacement therapy may reduce the risk of coronary heart disease but underlying mechanism has not been adequately explained. Recent data suggest that intercellular adhesion molecule 1 (ICAM-1) plays a critical role in early stage of atherosclerosis and may serve as a molecular marker for the development of arterial disease. We investigated the effects of oral and transdermal cyclic oestradiol combined with progesterone on plasma concentration of soluble ICAM-1 (sICAM-1). Thirty-seven healthy postmenopausal women were randomly assigned to receive either oral estradiol valerate or transdermal estradiol both combined with micronized progesterone or no hormonal treatment. Plasma sICAM-1 was assayed at baseline and after a 6-month period. Oral but not transdermal estradiol regimen significantly decreased mean value of sICAM-1 compared with no treatment. Differences in sICAM-1 levels between active treatments were significant. There were no significant changes in mean values of fibrinogen between the three groups. Our results show a favorable effect of oral estrogen plus progesterone on a soluble marker of vascular inflammation and may provide plausible explanation for a cardioprotective effect of hormone replacement therapy among healthy postmenopausal women.

 

  • References

  • 1 Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women. A statement for heathcare professionals from the American Heart Association.. Circulation 1997; 96: 2468-82.
    CrossrefPubMedSearch in Google Scholar
  • 2 Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status : influence of hormone replacement therapy.. Thromb Haemost 1993; 70: 584-7.
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Guetta V, Cannon III RO. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women.. Circulation 1996; 93: 1928-37.
    CrossrefPubMedSearch in Google Scholar
  • 4 Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO. Effets of hormone replacement therapy on fibrinolysis in postmenopausal women.. N Engl J Med 1997; 336: 683-90.
    CrossrefPubMedSearch in Google Scholar
  • 5 Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms, oxidation, inflammation, and genetics.. Circulation 1995; 91: 2488-96.
    CrossrefPubMedSearch in Google Scholar
  • 6 Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The Atherosclerosis Risk In Communities (ARIC) Study.. Circulation 1997; 96: 4219-25.
    CrossrefPubMedSearch in Google Scholar
  • 7 Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.. Lancet 1998; 351: 88-92.
    CrossrefPubMedSearch in Google Scholar
  • 8 Blann AD, Seigneur M, Steiner M, Miller JP, McCollum CN. Circulating ICAM-1 and VCAM-1 in peripheral artery disease and hypercholesterolemia: relationship to the location of atherosclerotic disease, smoking, and in the prediction of adverse events.. Thromb Haemost 1998; 79: 1080-5.
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17α-estradiol on cytokine-induced endothelial cell adhesion molecule expression.. J Clin Invest 1996; 98: 36-42.
    CrossrefPubMedSearch in Google Scholar
  • 10 Scarabin PY, Ahlenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.. Arterioscler Thromb Vasc Biol 1997; 17: 3071-8.
    CrossrefPubMedSearch in Google Scholar
  • 11 De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodart C, Conard J, Guyene TT, Mairon N, Corvol P, Guy-Grand B, Mauvais-Jarvis P, Sitruk-Ware R. Biological effects of estradiol-17α in postmenopausal women: oral versus percutaneous administration.. J Clin Endocrinol Metab 1986; 62: 536-41.
    CrossrefPubMedSearch in Google Scholar
  • 12 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogen.. Acta Haematol 1957; 17: 237-46.
    CrossrefPubMedSearch in Google Scholar
  • 13 Caulin-Glaser T, Farrell WJ, Pfau SE, Zaret B, Bunger K, Setaro J, Brennan JJ, Bender JR, Cleman MW, Cabin HS, Remetz MS. Modulation of circulating cellular adhesion molecules in postmenopausal women.. J Am Coll Cardiol 1998; 31: 1555-60.
    CrossrefPubMedSearch in Google Scholar
  • 14 Koh KK, Bui MN, Mincemoyer R, Cannon III RO. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women.. Am J Cardiol 1997; 80: 1505-7.
    CrossrefPubMedSearch in Google Scholar
  • 15 Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B. Vittinghoff E for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.. JAMA 1998; 280:: 605-13.
    CrossrefPubMedSearch in Google Scholar
  • 16 Oger E, Alhenc-Gelas M, Plu-Bureau G, Mennen L, Guize L, Scarabin PY.. Association of circulating ICAM-1 with menopausal status and hormone replacement therapy (submitted)..
  • 17 Beato M. Gene regulation by steroid hormones.. Cell 1989; 56: 335-44.
    CrossrefPubMedSearch in Google Scholar
  • 18 Ray A, Prefontaine KE, Ray P. Down-modulation of interleukine-6 gene expression by 17α-estradiol by the estrogen receptor.. J Biol Chem 1994; 269: 12940-6.
    PubMedSearch in Google Scholar
  • 19 Negre-Salvayre A, Pieraggi MT, Mabile L, Salvayre R. Protective effect of 17α-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells.. Atherosclerosis 1993; 99: 207-17.
    CrossrefPubMedSearch in Google Scholar
  • 20 Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women.. Lancet. 1994; 343: 269-70.
    CrossrefPubMedSearch in Google Scholar
  • 21 Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells.. J Clin Invest 1993; 92: 1866-74.
    CrossrefPubMedSearch in Google Scholar